Enhancing Tetrahydrocannabinol’s Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011

Background/Objectives: Current inflammatory bowel disease (IBD) treatments focus on symptomatic relief, highlighting the need for innovative approaches. Dysregulation of the cannabinoid 1 (CB1) receptor, part of the endocannabinoid system, is linked to colitis. While tetrahydrocannabinol (THC) allev...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmaceuticals (Basel, Switzerland) Ročník 18; číslo 2; s. 148
Hlavní autori:	Thapa, Dinesh, Patil, Mohan, Warne, Leon N, Carlessi, Rodrigo, Falasca, Marco
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 01.02.2025 MDPI
Predmet:	Ammonia Cannabidiol cannabinoid 1 receptor (CB1R) CB1R allosteric modulator Colon Diarrhea Drug therapy DSS-induced ulcerative colitis Homeostasis Inflammation Inflammatory bowel disease Inflammatory bowel diseases Nervous system agents Pain Testing Tetrahydrocannabinol tetrahydrocannabinol (THC) THC ZCZ011 Australia CB1R allosteric modulator ZCZ011 glucagon-like peptide 1 (GLP-1) cannabinoid 1 receptor (CB1R) ammonia cannabidiol (CBD) DSS-induced ulcerative colitis inflammatory bowel disease tetrahydrocannabinol (THC)
ISSN:	1424-8247, 1424-8247
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!